# Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection

> **NCT01858766** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 379 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** SOF
- **DRUG:** VEL
- **DRUG:** RBV

## Key facts

- **NCT ID:** NCT01858766
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2014-05
- **Final completion:** 2014-08
- **Target enrollment:** 379 (ACTUAL)
- **Last updated:** 2018-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01858766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01858766, "Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01858766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*